Daratumumab‐based induction and autologous transplantation in concomitant multiple myeloma and chronic myeloid leukemia

Abstract The coexistence of chronic myeloid leukemia (CML) and multiple myeloma (MM) is a rare clinical condition. By means of FISH and molecular analysis on both sorted CD138 plasma cells and cryopreserved CD34 stem cells, a distinct clonal origin of the hematological malignancies was demonstrated...

Full description

Bibliographic Details
Published in:	eJHaem
Main Authors:	Carmine Liberatore, Francesca Fioritoni, Annalisa Natale, Guido Montanaro, Gaetano La Barba, Cecilia Passeri, Ornella Iuliani, Bianca Fabi, Stefano Baldoni, Donatella Fantasia, Giuseppe Calabrese, Patrizia Accorsi, Stella Santarone, Stefano Pulini, Mauro Di Ianni
Format:	Article
Language:	English
Published:	Wiley 2023-11-01
Subjects:	CML multiple myeloma myeloma transplantation
Online Access:	https://doi.org/10.1002/jha2.765

Similar Items

Allogeneic stem cell transplantation in multiple myeloma: is there still a place?
by: Carmine Liberatore, et al.
Published: (2024-06-01)

Daratumumab–bortezomib–dexamethasone use in relapsed POEMS syndrome
by: Jahanzaib Khwaja, et al.
Published: (2022-08-01)

P24 HIGH-DOSE CYCLOPHOSPHAMIDE 4 GR/M2 AND STEM-CELL COLLECTION AFTER DARATUMUMAB-BASED QUADRUPLET INDUCTION IN NEWLY DIAGNOSED TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS: A SINGLE-CENTER EXPERIENCE
by: C. Liberatore, et al.
Published: (2023-05-01)

Daratumumab
by: Vishnu Gopal, et al.
Published: (2020-01-01)

Efficacy of Daratumumab‐Based Regimens for Extramedullary Pulmonary Plasmacytoma: A Case Report
by: Danilo De Novellis, et al.
Published: (2024-11-01)

Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease
by: Ja Min Byun, et al.
Published: (2022-10-01)

Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma
by: Cristina Gasparetto, et al.
Published: (2021-02-01)

Use of daratumumab in high risk multiple myeloma: A meta‐analysis
by: Vikram Premkumar, et al.
Published: (2020-07-01)

Higher cyclophosphamide dose grants optimal stem cell collection after daratumumab-based induction in multiple myeloma
by: Carmine Liberatore, et al.
Published: (2023-07-01)

Is There a Role for Daratumumab Retreatment in Patients with Relapsed/Refractory Multiple Myeloma?
by: Davor Galusic, et al.
Published: (2025-01-01)

Cytomegalovirus reactivation is frequent in multiple myeloma patients treated with daratumumab‐based regimens
by: Danilo De Novellis, et al.
Published: (2024-07-01)

High IKZF1/3 protein expression is a favorable prognostic factor for survival of relapsed/refractory multiple myeloma patients treated with lenalidomide
by: Maryam Pourabdollah, et al.
Published: (2016-11-01)

Daratumumab plus carfilzomib: An optimistic approach in relapsed/refractory multiple myeloma
by: A P Dubey, et al.
Published: (2020-01-01)

Daratumumab: A drug with transfusion dilemma
by: Amit Kumar Biswas, et al.
Published: (2023-01-01)

Daratumumab Treatment for “Truly Frail” Elderly Myeloma Patients
by: Yuichi Horigome, et al.
Published: (2024-03-01)

A case of fatal hyperammonaemic encephalopathy in a patient with end-stage Multiple Myeloma treated with daratumumab
by: Mauro Passucci, et al.
Published: (2023-01-01)

Clinical Challenges: Myeloma and Concomitant type 2 Diabetes
by: Yasar Albushra Abdul Rahiem Ahmed, et al.
Published: (2013-01-01)

Clinical challenges: Myeloma and concomitant Type 2 Diabetes
by: Yasar Albushra Abdul Rahiem Ahmed, et al.
Published: (2013-03-01)

Identifying clinical response to daratumumab therapy in relapsed/refractory multiple myeloma using a patient‐derived in vitro model
by: Niels vanNieuwenhuijzen, et al.
Published: (2024-02-01)

Combined Proteasome and Autophagy Inhibition in Relapsed/Refractory Multiple Myeloma—A Phase I Trial of Hydroxychloroquine, Carfilzomib, and Dexamethasone
by: Tobias S. Slørdahl, et al.
Published: (2025-02-01)

Best Practice for the Administration of Daratumumab in Multiple Myeloma: Australian Myeloma Nurse Expert Opinion
by: Tracy King, et al.
Published: (2018-01-01)

EFFECTS OF DARATUMUMAB ON HEMATOPOIETIC STEM CELLS IN PATIENTS WITH MULTIPLE MYELOMA WHO ARE PLANNED TO RECEIVE AUTOLOGOUS TRANSPLANTATION: WHAT’S THE RELEVANCE?
by: Pellegrino Musto, et al.
Published: (2024-08-01)

Serological responses against seasonal influenza viruses in patients with multiple myeloma treated or untreated with daratumumab after two doses of tetravalent vaccine
by: Simon B. Gressens, et al.
Published: (2024-09-01)

Anaplastic morphology in IgD multiple myeloma
by: Verónica Roldán Galiacho, et al.
Published: (2023-10-01)

Bilateral Bulky Adrenal Plasmacytomas with Very Good Response to Daratumumab-Based Therapy
by: Fang-Yu Wang, et al.
Published: (2023-04-01)

Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group
by: Francesca Fazio, et al.
Published: (2022-02-01)

Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma
by: Ilaria Saltarella, et al.
Published: (2020-01-01)

Daratumumab prevents programmed death ligand‐1 expression on antigen‐presenting cells in de novo multiple myeloma
by: Nicolas Stocker, et al.
Published: (2020-03-01)

Benefits of switching from intravenous to subcutaneous daratumumab: Perspectives from UK healthcare providers
by: Gordon Cook, et al.
Published: (2023-02-01)

Case Report: Invasive Fungal Infection and Daratumumab: A Case Series and Review of Literature
by: Francesca Farina, et al.
Published: (2022-07-01)

The Role of Radiotherapy for Patients With Multiple Myeloma in the Modern Era: A Real World Single‐Centre Experience
by: Dipal Mehta, et al.
Published: (2025-10-01)

A Report of a Symptomatic Progressive Myeloma during Pregnancy and Postpartum Period from Asymptomatic State
by: Gehad Elgabry, et al.
Published: (2023-05-01)

Isatuximab‐carfilzomib‐dexamethasone immediately after failing of the quadruplet Daratumumab‐bortezomib‐lenalidomide‐dexamethasone (Dara‐VRD): Striking response with no washout in a newly diagnosed multiple myeloma
by: Juan José Gil‐Fernández, et al.
Published: (2024-01-01)

Non-Competitive Binding of Isatuximab and Daratumumab to CD38: Implications for Targeted Therapy in Multiple Myeloma
by: Rubén Osuna-Gómez, et al.
Published: (2025-09-01)

Efficacy of daratumumab on multiple myeloma patients with renal insufficiency: a systematic review and meta-analysis
by: Hua Jiang, et al.
Published: (2024-12-01)

Cost-effectiveness and budget impact analysis of Daratumumab, Lenalidomide and dexamethasone for relapsed-refractory multiple myeloma
by: Zahra Goudarzi, et al.
Published: (2024-02-01)

Multiple Cranial Nerve Palsy Concomitant with Leptomeningeal Involvement in Multiple Myeloma: A Case Report and Review of Literature
by: Neda Pak, et al.
Published: (2018-01-01)

P144 | CYTOMEGALOVIRUS INFECTION AFTER AUTOLOGOUS STEM-CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA EXPOSED TO DARATUMUMAB
by: C. Liberatore, et al.
Published: (2025-09-01)

Economic Evaluation of Adding Daratumumab to Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma
by: Yi L, et al.
Published: (2024-11-01)

Acute myeloid leukemia synchronous with multiple myeloma successfully treated by azacytidine/lenalidomide and daratumumab without a decrease in myeloid clone size
by: Celine Berthon, et al.
Published: (2020-01-01)